On 1/30/25, Cardiff Oncology Inc (NASDAQ: CRDF) stock enjoyed a major increase of 15.1%, closing at $3.97. However, this advance was accompanied by unusually low trading volume at 60% of normal. Relative to the market the stock has been strong over the last nine months and has risen 12.1% during the last week.
Current PriceTarget Research Rating
Cardiff Oncology has a current Value Trend Rating of D (Negative). With this rating, PTR's two proprietary measures of a stock's current attractiveness are providing very contradictory signals. Cardiff Oncology has a very low Appreciation Score of 8 but a slightly positive Power Rating of 69, triggering the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.